Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

计划入组 70 人 · 首次发布于 2025 年 4 月 16 日

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

计划入组 1,300 人 · 首次发布于 2025 年 6 月 5 日

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

计划入组 875 人 · 首次发布于 2025 年 11 月 3 日

Acute Myeloid Leukemia(Advesya)

DCPS inhibitor (acute myeloid leukemia)

MYELOID THERAPEUTICS

United States

JAPAN ADULT LEUKEMIA STUDY GROUP

Japan

Bio-Path Holdings

United States

Forskolin Shows Dual Mechanism Against Aggressive KMT2A-Rearranged Acute Myeloid Leukemia

Syndax Pharmaceuticals' Niktimvo Approved for cGVHD, Revumenib Awaits FDA Decision

FDA Approves Revumenib for Relapsed/Refractory KMT2A-Rearranged Acute Leukemia